Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report.

Abstract

A 54-year-old woman was referred to hospital because of poor metabolic control. Clinical examination revealed marked acanthosis nigricans, and a striking lack of adipose tissue on the limbs, and excess fat deposits on the neck and face. She had been treated for diabetes since 2001 with high doses of insulin along with metformin. Clinical tests showed hypertriglyceridaemia with low high density lipoprotein (HDL) cholesterol, and cholestasis with mild cytolysis. Dunnigan syndrome (familial partial lipodystrophy type 2) was suspected and confirmed by molecular genetics. Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later. Diabetes related to mutations of the lamin A/C gene is difficult to treat because of severe insulin resistance. Nevertheless, therapy with pioglitazone resulted in marked and sustained improvements in metabolic control and insulin sensitivity.

• Authors: C Collet-Gaudillat, A Billon-Bancel, J-P Beressi
• Journal: Diabetes & metabolism (Diabetes Metab) Vol. 35 Issue 2 Pg. 151-4 (Apr 2009) ISSN: 1262-3636 [Print] France
• PMID: 19249234 (Publication Type: Case Reports, Journal Article)

Chemical References

• Hypoglycemic Agents
• Insulin
• LMNA protein, human
• Lamin Type A
• Thiazolidinediones
• Metformin
• Pioglitazone

Topics

• Adipose Tissue (pathology)
• Diabetes Mellitus (drug therapy, etiology, metabolism)
• Female
• Humans
• Hypoglycemic Agents (therapeutic use)
• Insulin (therapeutic use)
• Insulin Resistance
• Lamin Type A (genetics)
• Lipodystrophy, Familial Partial (complications, diagnosis, drug therapy, genetics)
• Metformin (therapeutic use)
• Middle Aged
• Pioglitazone
• Portugal
• Thiazolidinediones (therapeutic use)
• Treatment Outcome